Radioprotection of normal tissue cells

Strahlentherapie und Onkologie

Volumn 190, Issue 8, 2014, Pages 745-752

  Maier, Patrick ^a   Wenz, Frederik ^a   Herskind, Carsten ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Amifostine; Palifermin; Radiomitigators; Radioprotectors; Radiotherapy

Indexed keywords

AMIFOSTINE; ANTIINFLAMMATORY AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENTOLIMOD; FREE RADICAL; FUSED CARBON NITROGEN SULFUR HETEROCYCLE; GLUTATHIONE; GRAMICIDIN S; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MANGANESE; MULTIDRUG RESISTANCE PROTEIN 1; NITROXIDE; OXYGEN RADICAL; PIFITHRIN ALPHA; PIFITHRIN MU; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE; RECOMBINANT FIBROBLAST GROWTH FACTOR; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL DEATH; CLONOGENESIS; CLONOGENIC ASSAY; DNA DAMAGE; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; NONHUMAN; RADIATION PROTECTION; RADIATION RESPONSE; RADIOSENSITIVITY; WHOLE BODY RADIATION; XEROSTOMIA;

AMIFOSTINE; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; DNA DAMAGE; DOSE FRACTIONATION; FIBROBLAST GROWTH FACTOR 7; FREE RADICAL SCAVENGERS; HUMANS; LINEAR ENERGY TRANSFER; OTORHINOLARYNGOLOGIC NEOPLASMS; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; REACTIVE OXYGEN SPECIES; TUMOR CELLS, CULTURED; WHOLE-BODY IRRADIATION;

EID: 84906935312     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-014-0637-x     Document Type: Article

References (110)

1. Bhide SA, Nutting CM (2010) Recent advances in radiotherapy. BMC Med 8:25
2. Lo SS, Fakiris AJ, Chang EL et al (2010) Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol 7:44-54
3. Tipton K, Launders JH, Inamdar R, Miyamoto C, Schoelles K (2011) Stereotactic body radiation therapy: scope of the literature. Ann Intern Med 154:737-745
4. Baskar R, Lee KA, Yeo R, Yeoh KW (2012) Cancer and radiation therapy: current advances and future directions. Int J Med Sci 9:193-199
5. Purdy JA (2008) Dose to normal tissues outside the radiation therapy patient's treated volume: a review of different radiation therapy techniques. Health Phys 95:666-676
6. Wenz F, Tiefenbacher U, Willeke F, Weber KJ (2001) The search for therapeutic gain in radiation oncology. Onkologie 24:51-55 (Pubitemid 34701785)
7. Verellen D, Ridder MD, Linthout N, Tournel K et al (2007) Innovations in image-guided radiotherapy. Nat Rev Cancer 7:949-960 (Pubitemid 350165868)
8. Stieler F, Wenz F, Shi M, Lohr F (2013) A novel surface imaging system for patient positioning and surveillance during radiotherapy: a phantom study and clinical evaluation. Strahlenther Onkol 189:938-944
9. Bentzen SM, Gregoire V (2011) Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol 21:101-110
10. Ch'ang HJ, Maj JG, Paris F et al (2005) ATM regulates target switching to escalating doses of radiation in the intestines. Nat Med 11:484-490 (Pubitemid 40685970)
11. Dainiak N (2002) Hematologic consequences of exposure to ionizing radiation. Exp Hematol 30:513-528
12. Haimovitz-Friedman A, Kolesnick RN, Fuks Z (1997) Differential inhibition of radiation-induced apoptosis. Stem Cells 15:43-47 (Pubitemid 27494838)
13. Paris F, Fuks Z, Kang A et al (2001) Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293:293-297 (Pubitemid 32694744)
14. Scott SD, Greco O (2004) Radiation and hypoxia inducible gene therapy systems. Cancer Metastasis Rev 23:269-276 (Pubitemid 38881811)
15. Cordes N, Rodel F, Rodemann HP (2012) Molecular signaling pathways. Mechanisms and clinical use. Strahlenther Onkol 188:308-311
16. Stewart FA, Akleyev AV, Hauer-Jensen M et al (2012) ICRP publication 118: ICRP statement on tissue reactions and early and late effects of radiation in normal tissues and organs-threshold doses for tissue reactions in a radiation protection context. Ann ICRP 41:211-286
17. Bourgier C, Levy A, Vozenin MC, Deutsch E (2012) Pharmacological strategies to spare normal tissues from radiation damage: useless or overlooked therapeutics? Cancer Metastasis Rev 31:699-712
18. Maier P, Veldwijk MR, Wenz F (2011) Radioprotective gene therapy. Expert Opin Biol Ther 11:1135-1151
19. Herskind C (1988) Sulfhydryl protection and the oxygen effect on radiation-induced inactivation of r-chromatin in vitro. Influence of an OH scavenger: t-butanol. Radiat Res 115:141-151
20. Yuhas JM, Storer JB (1969) Differential chemoprotection of normal and malignant tissues. J Natl Cancer Inst 42:331-335
21. Calabro-Jones PM, Fahey RC, Smoluk GD, Ward JF (1985) Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol Relat Stud Phys Chem Med 47:23-27 (Pubitemid 15139195)
22. Yuhas JM (1980) Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)- ethylphosphorothioic acid. Cancer Res 40:1519-1524
23. Savoye C, Swenberg C, Hugot S et al (1997) Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage. Int J Radiat Biol 71:193-202 (Pubitemid 27162860)
24. Kouvaris JR, Kouloulias VE, Vlahos LJ (2007) Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 12:738-747 (Pubitemid 47036208)
25. Sasse AD, Clark LG, Sasse EC, Clark OA (2006) Amifostine reduces side effects and improves complete response rate during radiotherapy: results of a meta-analysis. Int J Radiat Oncol Biol Phys 64:784-791 (Pubitemid 43183575)
26. Mell LK, Malik R, Komaki R et al (2007) Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis. Int J Radiat Oncol Biol Phys 68:111-118 (Pubitemid 46589830)
27. Movsas B, Scott C, Langer C et al (2005) Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23:2145-2154 (Pubitemid 46218706)
28. Koukourakis MI, Maltezos E (2006) Amifostine administration during radiotherapy for cancer patients with genetic, autoimmune, metabolic and other diseases. Anticancer Drugs 17:133-138
29. Vos O (1992) Role of endogenous thiols in protection. Adv Space Res 12:201-207
30. Chatterjee A (2013) Reduced glutathione: a radioprotector or a modulator of DNA-repair activity? Nutrients 5:525-542
31. Meister A (1983) Selective modification of glutathione metabolism. Science 220:472-477
32. Russo A, Mitchell JB (1984) Radiation response of Chinese hamster cells after elevation of intracellular glutathione levels. Int J Radiat Oncol Biol Phys 10:1243-1247 (Pubitemid 14029871)
33. Russo A, Mitchell JB, Finkelstein E, DeGraff WG et al (1985) The effects of cellular glutathione elevation on the oxygen enhancement ratio. Radiat Res 103:232-239 (Pubitemid 15007463)
34. Mazur L (2000) Radioprotective effects of the thiols GSH and WR-2721 against X-ray-induction of micronuclei in erythroblasts. Mutat Res 468:27-33
35. Chaudhuri JP, Langendorff H (1968) Chemical radioprotection of mammalian chromosomes in vivo: radioprotection of rat bone-marrow chromosomes with a single prophylactic dose of AET. Int J Radiat Biol Relat Stud Phys Chem Med 14:463-467
36. Chatterjee A, Jacob-Raman M, Mohapatra B (1989) Potentiation of bleomycin-induced chromosome aberrations by the radioprotector reduced glutathione. Mutat Res 214:207-213 (Pubitemid 19245412)
37. Louie KG, Behrens BC, Kinsella TJ et al (1985) Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer Res 45:2110-2115 (Pubitemid 15024393)
38. Biaglow JE, Ayene IS, Koch CJ et al (2003) Radiation response of cells during altered protein thiol redox. Radiat Res 159:484-494 (Pubitemid 36397770)
39. Pujari G, Berni A, Palitti F, Chatterjee A (2009) Influence of glutathione levels on radiation-induced chromosomal DNA damage and repair in human peripheral lymphocytes. Mutat Res 675:23-28
40. Ray S, Chatterjee A (2007) Influence of glutathione on the induction of chromosome aberrations, delay in cell cycle kinetics and cell cycle regulator proteins in irradiated mouse bone marrow cells. Int J Radiat Biol 83:347-354 (Pubitemid 46676532)
41. Herskind C, Westergaard O (1986) Inactivation of a single eucaryotic gene irradiated in vitro in transcriptionally active chromatin form. Radiat Res 106:331-344 (Pubitemid 16060492)
42. Herskind C, Westergaard O (1988) Variable protection by OH scavengers against radiation-induced inactivation of isolated transcriptionally active chromatin: the influence of secondary radicals. Radiat Res 114:28-41
43. Vorotnikova E, Rosenthal RA, Tries M, Doctrow SR, Braunhut SJ (2010) Novel synthetic SOD/catalase mimetics can mitigate capillary endothelial cell apoptosis caused by ionizing radiation. Radiat Res 173:748-759
44. Zelko IN, Mariani TJ, Folz RJ (2002) Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 33:337-349 (Pubitemid 34790245)
45. Akashi M, Hachiya M, Paquette RL et al (1995) Irradiation increases manganese superoxide dismutase mRNA levels in human fibroblasts. Possible mechanisms for its accumulation. J Biol Chem 270:15864-15869
46. Greenberger JS, Epperly MW (2007) Review. Antioxidant gene therapeutic approaches to normal tissue radioprotection and tumor radiosensitization. Vivo 21:141-146 (Pubitemid 46534266)
47. Gauter-Fleckenstein B, Fleckenstein K, Owzar K et al (2008) Comparison of two Mn porphyrin-based mimics of superoxide dismutase in pulmonary radioprotection. Free Radic Biol Med 44:982-989
48. Rabbani ZN, Batinic-Haberle I, Anscher MS et al (2007) Long-term administration of a small molecular weight catalytic metalloporphyrin antioxidant, AEOL 10150, protects lungs from radiation-induced injury. Int J Radiat Oncol Biol Phys 67:573-580 (Pubitemid 46108330)
49. Vujaskovic Z, Batinic-Haberle I, Rabbani ZN et al (2002) A small molecular weight catalytic metalloporphyrin antioxidant with superoxide dismutase (SOD) mimetic properties protects lungs from radiation-induced injury. Free Radic Biol Med 33:857-863 (Pubitemid 35232320)
50. Doctrow SR, Huffman K, Marcus CB et al (2002) Salen-manganese complexes as catalytic scavengers of hydrogen peroxide and cytoprotective agents: structure-activity relationship studies. J Med Chem 45:4549-4558
51. Rosenthal RA, Fish B, Hill RP et al (2011) Salen Mn complexes mitigate radiation injury in normal tissues. Anticancer Agents Med Chem 11:359-372
52. Gao F, Fish BL, Szabo A et al (2012) Short-term treatment with a SOD/catalase mimetic, EUK-207, mitigates pneumonitis and fibrosis after single-dose total-body or whole-thoracic irradiation. Radiat Res 178:468-480
53. Doctrow SR, Lopez A, Schock AM et al (2013) A synthetic superoxide dismutase/catalase mimetic EUK-207 mitigates radiation dermatitis and promotes wound healing in irradiated rat skin. J Invest Dermatol 133:1088-1096
54. Goff JP, Epperly MW, Dixon T et al (2011) Radiobiologic effects of GS-nitroxide (JP4-039) on the hematopoietic syndrome. Vivo 25:315-323
55. Epperly MW, Goff JP, Li S et al (2010) Intraesophageal administration of GS-nitroxide (JP4-039) protects against ionizing irradiation-induced esophagitis. Vivo 24:811-819
56. Veldwijk MR, Herskind C, Laufs S et al (2004) Recombinant adeno-associated virus 2-mediated transfer of the human superoxide-dismutase gene does not confer radioresistance on HeLa cervical carcinoma cells. Radiother Oncol 72:341-350 (Pubitemid 39265389)
57. Veldwijk MR, Trah J, Wang M et al (2011) Overexpression of manganese superoxide dismutase does not increase clonogenic cell survival despite effect on apoptosis in irradiated lymphoblastoid cells. Radiat Res 176:725-731
58. Zhong W, Oberley LW, Oberley TD et al (1996) Inhibition of cell growth and sensitization to oxidative damage by overexpression of manganese superoxide dismutase in rat glioma cells. Cell Growth Differ 7:1175-1186 (Pubitemid 26360698)
59. Epperly MW, Defilippi S, Sikora C et al (2000) Intratracheal injection of manganese superoxide dismutase (MnSOD) plasmid/liposomes protects normal lung but not orthotopic tumors from irradiation. Gene Ther 7:1011-1018 (Pubitemid 30398349)
60. Guo H, Seixas-Silva JA Jr, Epperly MW et al (2003) Prevention of radiation-induced oral cavity mucositis by plasmid/liposome delivery of the human manganese superoxide dismutase (SOD2) transgene. Radiat Res 159:361-370 (Pubitemid 36314951)
61. Delanian S, Martin M, Bravard A et al (2001) Cu/Zn superoxide dismutase modulates phenotypic changes in cultured fibroblasts from human skin with chronic radiotherapy damage. RadiotherOncol 58:325-331 (Pubitemid 32181868)
62. Epperly MW, Bray JA, Krager S et al (1999) Intratracheal injection of adenovirus containing the human MnSOD transgene protects athymic nude mice from irradiation-induced organizing alveolitis. IntJRadiatOncolBiolPhys 43:169-181 (Pubitemid 29065842)
63. Sun J, Chen Y, Li M, Ge Z (1998) Role of antioxidant enzymes on ionizing radiation resistance. Free RadicBiolMed 24:586-593 (Pubitemid 28150477)
64. Veldwijk MR, Herskind C, Sellner L et al (2009) Normal-tissue radioprotection by overexpression of the copper-zinc and manganese superoxide dismutase genes. Strahlenther Onkol 185:517-523
65. Tarhini AA, Belani CP, Luketich JD et al (2011) A phase I study of concurrent chemotherapy (paclitaxel and carboplatin) and thoracic radiotherapy with swallowed manganese superoxide dismutase plasmid liposome protection in patients with locally advanced stage III non-small-cell lung cancer. Hum Gene Ther 22:336-342
66. Maier P, Herskind C, Fleckenstein K et al (2008) MDR1 gene transfer using a lentiviral SIN vector confers radioprotection to human CD34+ hematopoietic progenitor cells. Radiat Res 169:301-310 (Pubitemid 351521765)
67. Komarov PG, Komarova EA, Kondratov RV et al (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285:1733-1737 (Pubitemid 29428873)
68. Gudkov AV, Komarova EA (2007) Dangerous habits of a security guard: the two faces of p53 as a drug target. Hum Mol Genet 16:R67-R72 (Pubitemid 47241844)
69. Gudkov AV, Komarova EA (2010) Radioprotection: smart games with death. J Clin Invest 120:2270-2273
70. Strom E, Sathe S, Komarov PG et al (2006) Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol 2:474-479 (Pubitemid 44266309)
71. Leonova KI, Shneyder J, Antoch MP et al (2010) A small molecule inhibitor of p53 stimulates amplification of hematopoietic stem cells but does not promote tumor development in mice. Cell Cycle 9:1434-1443
72. Christophorou MA, Ringshausen I, Finch AJ et al (2006) The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443:214-217 (Pubitemid 44387609)
73. Sinn B, Schulze J, Schroeder G et al (2010) Pifithrin-alpha as a potential cytoprotective agent in radiotherapy: protection of normal tissue without decreasing therapeutic efficacy in glioma cells. Radiat Res 174:601-610
74. Finch PW, Rubin JS, Miki T et al (1989) Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science 245:752-755 (Pubitemid 19214010)
75. Miki T, Fleming TP, Bottaro DP et al (1991) Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop. Science 251:72-75 (Pubitemid 21916854)
76. Finch PW, Rubin JS (2006) Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors. J Natl Cancer Inst 98:812-824 (Pubitemid 43923439)
77. Wildhaber BE, Yang H, Teitelbaum DH (2003) Keratinocyte growth factor decreases total parenteral nutrition-induced apoptosis in mouse intestinal epithelium via Bcl-2. J Pediatr Surg 38:92-96 (discussion 92-96)
78. Niture SK, Jaiswal AK (2013) Nrf2-induced antiapoptotic Bcl-xL protein enhances cell survival and drug resistance. Free Radic Biol Med 57:119-131
79. Braun S, Hanselmann C, Gassmann MG et al (2002) Nrf2 transcription factor, a novel target of keratinocyte growth factor action which regulates gene expression and inflammation in the healing skin wound. Mol Cell Biol 22:5492-5505 (Pubitemid 34755759)
80. Niture SK, Khatri R, Jaiswal AK (2014) Regulation of Nrf2-an update. Free Radic Biol Med 66:36-44
81. Spielberger R, Stiff P, Bensinger W et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590-2598 (Pubitemid 39628580)
82. Stiff PJ, Emmanouilides C, Bensinger WI et al (2006) Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 24:5186-5193 (Pubitemid 46646481)
83. Raber-Durlacher JE, von Bultzingslowen I, Logan RM et al (2013) Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer 21:343-355
84. Alvarez E, Fey EG, Valax P et al (2003) Preclinical characterization of CG53135 (FGF-20) in radiation and concomitant chemotherapy/radiation-induced oral mucositis. Clin Cancer Res 9:3454-3461 (Pubitemid 37082744)
85. Steiling H, Werner S (2003) Fibroblast growth factors: key players in epithelial morphogenesis, repair and cytoprotection. Curr Opin Biotechnol 14:533-537 (Pubitemid 37298040)
86. Schuster MW, Shore TB, Harpel JG et al (2008) Safety and tolerability of velafermin (CG53135-05) in patients receiving high-dose chemotherapy and autologous peripheral blood stem cell transplant. Support Care Cancer 16:477-483 (Pubitemid 351502754)
87. Freytes CO, Ratanatharathorn V, Taylor C et al (2004) Phase I/II randomized trial evaluating the safety and clinical effects of repifermin administered to reduce mucositis in patients undergoing autologous hematopoietic stem cell transplantation. Clin Cancer Res 10:8318-8324 (Pubitemid 40053392)
88. Kim SB, Pandita RK, Eskiocak U et al (2012) Targeting of Nrf2 induces DNA damage signaling and protects colonic epithelial cells from ionizing radiation. Proc Natl Acad Sci USA 109:E2949-E2955
89. Mustata G, Li M, Zevola N et al (2011) Development of small-molecule PUMA inhibitors for mitigating radiation-induced cell death. Curr Top Med Chem 11:281-290
90. Inoue A, Seidel MG, Wu W et al (2002) Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer cell 2:279-288 (Pubitemid 41043962)
91. Maier P, Herskind C, Barzan D, Zeller WJ, Wenz F (2010) SNAI2 as a novel radioprotector of normal tissue by gene transfer using a lentiviral bicistronic SIN vector. Radiat Res 173:612-619
92. Gottesman MM, Ling V (2006) The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS letters 580:998-1009 (Pubitemid 43185280)
93. Ruefli AA, Tainton KM, Darcy PK, Smyth MJ, Johnstone RW (2002) P-glycoprotein inhibits caspase-8 activation but not formation of the death inducing signal complex (disc) following Fas ligation. Cell Death Differ 9:1266-1272 (Pubitemid 35331774)
94. Tainton KM, Smyth MJ, Jackson JT et al (2004) Mutational analysis of P-glycoprotein: suppression of caspase activation in the absence of ATP-dependent drug efflux. Cell Death Differ 11:1028-1037 (Pubitemid 39232362)
95. Belka C, Rudner J, Wesselborg S et al (2000) Differential role of caspase-8 and BID activation during radiation- and CD95-induced apoptosis. Oncogene 19:1181-1190 (Pubitemid 30157548)
96. Maier P, Fleckenstein K, Li L et al (2006) Overexpression of MDR1 using a retroviral vector differentially regulates genes involved in detoxification and apoptosis and confers radioprotection. Radiat Res 166:463-473 (Pubitemid 44353429)
97. Tallant T, Deb A, Kar N et al (2004) Flagellin acting via TLR5 is the major activator of key signaling pathways leading to NF-kappa B and proinflammatory gene program activation in intestinal epithelial cells. BMC Microbiol 4:33
98. Burdelya LG, Krivokrysenko VI, Tallant TC et al (2008) An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320:226-230 (Pubitemid 351521417)
99. Wang ZD, Qiao YL, Tian XF et al (2012) Toll-like receptor 5 agonism protects mice from radiation pneumonitis and pulmonary fibrosis. Asian Pac J Cancer Prev 13:4763-4767
100. Zhou SX, Li FS, Qiao YL et al (2012) Toll-like receptor 5 agonist inhibition of growth of A549 lung cancer cells in vivo in a Myd88 dependent manner. Asian Pac J Cancer Prev 13:2807-2812
101. Fry DW, Harvey PJ, Keller PR et al (2004) Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther 3:1427-1438
102. Toogood PL, Harvey PJ, Repine JT et al (2005) Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem 48:2388-2406 (Pubitemid 40516432)
103. Zhu G, Conner SE, Zhou X et al (2003) Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J Med Chem 46:2027-2030 (Pubitemid 36583483)
104. Johnson SM, Torrice CD, Bell JF et al (2010) Mitigation of hematologic radiation toxicity in mice through pharmacological quiescence induced by CDK4/6 inhibition. J Clin Invest 120:2528-2536
105. Collins I, Garrett MD (2005) Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 5:366-373 (Pubitemid 40932038)
106. Chernikova SB, Game JC, Brown JM (2012) Inhibiting homologous recombination for cancer therapy. Cancer Biol Ther 13:61-68
107. Liang Y, Lin SY, Brunicardi FC et al (2009) DNA damage response pathways in tumor suppression and cancer treatment. World J Surg 33:661-666
108. Greenberger JS (2009) Radioprotection. Vivo 23:323-336
109. Erenpreisa J, Kalejs M, Cragg MS (2005) Mitotic catastrophe and endomitosis in tumour cells: an evolutionary key to a molecular solution. Cell Biol Int 29:1012-1018 (Pubitemid 41739825)
110. Nguyen T, Nioi P, Pickett CB (2009) The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284:13291-13295